A Phase I Study to Investigate the Relative Bioavailability of Modified-release Formulations of AZD1446 Compared to an Immediate-release Capsule Under Fed and Fasting Conditions Following Single and Repeated Dose Administration to Young and Elderly Healthy Volunteers.

Trial Profile

A Phase I Study to Investigate the Relative Bioavailability of Modified-release Formulations of AZD1446 Compared to an Immediate-release Capsule Under Fed and Fasting Conditions Following Single and Repeated Dose Administration to Young and Elderly Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2015

At a glance

  • Drugs AZD 1446 (Primary)
  • Indications Alzheimer's disease; Attention-deficit hyperactivity disorder
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Aug 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 26 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top